# 关于Chad Spooner 2025年5月，美敦力宣布计划将其糖尿病业务分拆为一家独立的、公开上市的公司，预计在 18个月内 完成分 离。MiniMed将继承美敦力在糖尿病管理领域的创新传统， 专注于提供完整的胰岛素管理系统，包括自动胰 岛素泵、连续血糖监测仪（CGM）和智能胰岛素笔等产品 。 2025年7月8日， Medtronic（美敦力） 宣布， Chad Spooner将于2025年7月14日起正式出任其糖尿病业 务部门 MiniMed 的首席财务官（CFO） 。此次任命正值Medtronic计划将糖尿病业务分拆为一家独立上市公 司之际，旨在为该业务板块的独立运营和未来发展奠定财务与战略基础。 Chad Spooner 拥有超过25年的财务领导经验，横跨医疗、消费品和工业领域，具备丰富的企业转型、财务 战略和资本市场运作经验。以下是其关键职业经历： 高管评价 BIC集团（BIC Group）CFO ：在加入Medtronic之前，Spooner担任全球消费品公司BIC的 首席财务 官 ，负责全球财务战略、投资者关系及企业并购事务。 Tenex Capital Management ：他曾联合创办 ...

Key Takeaways Dexcom saw record new patient starts and expanded T2D access coverage in Q1 2025. Dexcom's 15-day G7 and OTC Stelo drive innovation and support long-term commercial growth. Dexcom faces margin pressure from freight costs, inflation and an ongoing FDA warning letter.DexCom (DXCM) delivered robust first-quarter 2025 results, underpinned by strong category demand, record new patient growth and meaningful progress in its long-term strategic initiatives. As the year progresses, several key growth ...

Core Viewpoint - Medtronic is strategically establishing a Global Capability Centre in Pune, India, to support its diabetes business spin-off, MiniMed, reflecting a focus on global resource allocation and innovation service models [1][6][20]. Group 1: Global Capability Centre in Pune - The Pune centre is expected to create 300 jobs in its first year, expanding to 600 over four years, and will serve as an "excellence operations platform" integrating technology and customer support for global diabetes operations [3][11]. - The centre's establishment is part of a systematic approach to support MiniMed's global operational framework, indicating a proactive strategy rather than a defensive measure [8][20]. Group 2: MiniMed's Formation and Strategy - Medtronic plans to complete the spin-off of its diabetes business into MiniMed within 18 months, with an IPO for up to 20% of shares, while the remaining will be distributed to existing shareholders [6][12]. - MiniMed will focus on developing a comprehensive insulin management ecosystem, including automated insulin delivery systems and smart multi-dose injection solutions [13][16]. Group 3: Market Potential and Local Advantages - India has the second-largest number of diabetes patients globally, with projections indicating over 100 million diagnosed by 2025, and the diabetes care market is expected to grow from ₹1.25 trillion in 2024 to ₹1.87 trillion by 2030, at a CAGR of nearly 8% [9][11]. - Pune's local talent pool and digital infrastructure make it an ideal location for Medtronic's new centre, enhancing its capabilities in remote healthcare and AI [11]. Group 4: Competitive Landscape - MiniMed faces increasing competition from companies like Tandem Diabetes Care and Beta Bionics, which are advancing in wearable pump design and smart feedback algorithms [19]. - The success of MiniMed will depend on its ability to quickly translate the digital capabilities from the Pune centre into product upgrades to maintain competitiveness in the market [19]. Group 5: Conclusion - The establishment of the Pune centre is a strategic move for Medtronic to enhance its operational capabilities and profitability while transitioning MiniMed into a solution provider in the diabetes management space [20].

(Photo Illustration by Cheng Xin/Getty Images)Getty ImagesDeal OverviewOn May 21, 2025, Medtronic plc (NYSE: MDT; $87.44, Market Capitalization: $112.1 billion), a global leader in medical technology, announced its intent to spin off its Diabetes business into a standalone entity (New Diabetes Company). This strategic move is designed to streamline Medtronic’s portfolio, sharpen its focus on high-margin growth areas, and unlock shareholder value.Post spin-off, Medtronic (RemainCo) will continue to operate a ...

Over the past few years, Medtronic (MDT 0.80%) has faced significant challenges, including a pandemic-induced slowdown, relatively slow revenue growth, and economic issues that impacted its financial results. Throughout it all, Medtronic's diabetes care business has consistently been one of its fastest-growing segments.However, the healthcare leader recently announced some news regarding this unit that might surprise some investors. Let's find out more about it and discuss what it means for Medtronic's pros ...

Core Viewpoint - Medtronic is facing challenges in the fiscal fourth quarter of 2025 due to rising costs, geopolitical pressures, and declining earnings estimates despite previous earnings beats [3][4][6]. Financial Performance - Medtronic's adjusted earnings for the last reported quarter were $1.39, exceeding the Zacks Consensus Estimate by 2.21% [1] - The Zacks Consensus Estimate for fiscal fourth-quarter revenues is $8.81 billion, indicating a year-over-year growth of 2.6% [2] - The consensus estimate for fourth-quarter earnings is $1.58 per share, reflecting an 8.2% rise year-over-year [2] - Earnings estimates for the fourth quarter have declined by 1.9% over the past 90 days [2] Challenges and Headwinds - Rising costs and expenses due to inflation and geopolitical pressures are impacting profitability [3] - The tariff environment is affecting financial outlook, particularly due to Medtronic's manufacturing presence in Mexico and Canada [4] - Lower procedural volumes in elective surgeries and other medical procedures are putting pressure on the bottom line [6] - Unfavorable currency movements are expected to negatively impact revenues by $125 million to $175 million in the fourth quarter [8] Growth Opportunities - Despite challenges, Medtronic has shown resilience with mid-single-digit organic revenue growth [9] - Key growth areas include pulse field ablation, TAVR, neuromodulation, and diabetes businesses, driven by new product launches [10][12][13] - The company has made foundational changes to improve operations and is focusing on fast-growth MedTech markets [15][16] Market Position - Medtronic's stock has declined 5.9% in the fiscal fourth quarter, underperforming compared to industry peers [20] - The company's shares trade at a Price/Earnings ratio of 14.24X, below the industry average of 21.71X and the S&P 500's 20.43X [24][25] Conclusion - Medtronic has significant long-term growth potential but faces macroeconomic headwinds and rising expenses that could impact bottom-line growth [26]

Medtronic (MDT) Q3 2025 Earnings Call February 18, 2025 08:00 AM ET Company Participants Ryan Weispfenning - VP & Head of Investor RelationsGeoff Martha - Chairman and Chief Executive OfficerGary Corona - SVP - Corporate FinanceBrad Welnick - Vice President, Global FP&A and Investor RelationsPatrick Wood - Managing DirectorSean Salmon - Executive VP & President of Cardiovascular PortfolioVijay Kumar - Senior Managing DirectorMike Marinaro - Executive VP and President of Medical Surgical Portfolio & Surgical ...